Teprasiran

Summary

Teprasiran (CHEMBL4297574) is a phase-3 clinical-stage oligonucleotide; indicated across 1 condition including acute kidney injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 1 condition
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297574
Name	Teprasiran
Type	Oligonucleotide
Max phase	3

Also known as: I5NP, Qpi-1002, QPI-1002, Teprasiran, TEPRASIRAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acute kidney injury	2	MONDO:0002492	HP:0001919

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1/PHASE2	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02610296	PHASE3	COMPLETED	QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
NCT03510897	PHASE3	TERMINATED	QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
NCT00802347	PHASE1/PHASE2	COMPLETED	I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation
NCT02610283	PHASE2	COMPLETED	A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
NCT00683553	PHASE1	TERMINATED	A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).